Tag: development program

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

Humboldt Seed Company and Marley Family Launch Two New Cannabis Seed Strains

Globally recognized cannabis brand honors Bob Marley with release of Redemption and One Love cannabis seeds.SAN FRANCISCO, June 9, 2026 /PRNewswire/ -- Humboldt Seed...

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...

Thea Energy Accelerates Fusion Energy with Helios Power Plant Digital Twin and AI Surrogate Models in Collaboration with NVIDIA, Synopsys, Argonne National Laboratory, and...

The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Yangarra Resources Ltd. Announces Expanded 2026 Capital Program and Increased Credit Facility

Yangarra Resources Ltd. provides an operations update, an increase to its capital budget and an update to its credit facility.

American Fusion Inc. (OTC: AMFN) Expands Intellectual Property Portfolio with Patent Application Covering Future Commercial Texatron™ Fusion Engine™ Systems

American Fusion Expands Intellectual Property Portfolio with Patent Application

Dried Plasma Innovation Addresses Critical Global Need

Velico's FrontlineODP™ Spray Dried Plasma Achieves Key Milestone with First-in-Human Safety Trial BEVERLY, Mass., Aug. 14, 2025 /PRNewswire/ -- Trauma doesn't wait, and neither should...

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsDevelopment program

Government of Canada supports the 37th Francos de Montréal

FSK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Investor...

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI